These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25104444)

  • 1. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice.
    Gil EY; Jo UH; Lee HJ; Kang J; Seo JH; Lee ES; Kim YH; Kim I; Phan-Lai V; Disis ML; Park KH
    Breast Cancer Res Treat; 2014 Aug; 147(1):69-80. PubMed ID: 25104444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
    Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
    Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
    Jabrane-Ferrat N; Campbell MJ; Esserman LJ; Peterlin BM
    Cancer Gene Ther; 2006 Nov; 13(11):1002-10. PubMed ID: 16841083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.
    Nava-Parada P; Forni G; Knutson KL; Pease LR; Celis E
    Cancer Res; 2007 Feb; 67(3):1326-34. PubMed ID: 17283170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.
    Astolfi A; Landuzzi L; Nicoletti G; De Giovanni C; Croci S; Palladini A; Ferrini S; Iezzi M; Musiani P; Cavallo F; Forni G; Nanni P; Lollini PL
    Am J Pathol; 2005 Apr; 166(4):1205-16. PubMed ID: 15793299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.
    Pupa SM; Invernizzi AM; Forti S; Di Carlo E; Musiani P; Nanni P; Lollini PL; Meazza R; Ferrini S; Menard S
    Gene Ther; 2001 Jan; 8(1):75-9. PubMed ID: 11402305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer stem cells and cells of origin in MMTV-Her2/neu-induced mammary tumorigenesis.
    Lo PK; Chen H
    Oncogene; 2013 Mar; 32(10):1338-40. PubMed ID: 23045276
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice.
    Koman IE; Commane M; Paszkiewicz G; Hoonjan B; Pal S; Safina A; Toshkov I; Purmal AA; Wang D; Liu S; Morrison C; Gudkov AV; Gurova KV
    Cancer Prev Res (Phila); 2012 Aug; 5(8):1025-35. PubMed ID: 22689915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine.
    Park JM; Terabe M; Steel JC; Forni G; Sakai Y; Morris JC; Berzofsky JA
    Cancer Res; 2008 Mar; 68(6):1979-87. PubMed ID: 18339880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
    Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
    Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
    Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
    Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
    Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
    Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
    Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
    Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.
    Knutson KL; Disis ML
    Clin Breast Cancer; 2001 Apr; 2(1):73-9. PubMed ID: 11899386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice.
    Parris AB; Zhao Q; Howard EW; Zhao M; Ma Z; Yang X
    J Exp Clin Cancer Res; 2017 Feb; 36(1):28. PubMed ID: 28193239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.